SHILPAMED Shilpa Medicare Ltd Other Situations Announcement 2025 - CEP Approval Received Shilpa Pharma Lifesciences Limited has received a CEP from EDQM for its API, Teriflunomide, which is used in treating multiple sclerosis and is effective with oral administration. This is the 25th CEP issued to Shilpa by EDQM, highlighting its commitment to quality products..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Shilpa Medicare Ltd